Stopped: COVID restrictions prohibit further study activies
This open-label study will determine if chlorthalidone is safe and effective for the use of reducing urinary calcium excretion over 4 weeks in subjects with type 1 diabetes
Age range
12 Years – 21 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Urinary Calcium Excretion
Timeframe: Assessed at baseline and at 4 weeks
Hypokalemia
Timeframe: Assessed weekly for up to 4 weeks or until hypokalemia develops
Hypercalcemia
Timeframe: Assessed weekly for up to 4 weeks or until hypercalcemia develops
Hyperglycemia
Timeframe: Assessed at baseline and at 4 weeks